Skip to main content

Advertisement

Log in

Ligustilide ameliorates cognitive impairment via AMPK/SIRT1 pathway in vascular dementia rat

  • Original Article
  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

Abstract

Vascular dementia (VaD) is the second cause of dementia after Alzheimer’s disease. Ligustilide (LIG) is one of the main active ingredients of traditional Chinese medicines, such as Angelica. Studies have reported that LIG could protect against VaD. However, the mechanism is still confused. In this study, we employed a bilateral common carotid artery occlusion rat model to study. LIG (20 or 40 mg/kg/day) and Nimodipine (20 mg/kg) were orally administered to the VaD rats for four weeks. Morris water maze test showed that LIG effectively ameliorated learning and memory impairment in VaD rats. LIG obviously reduced neuronal oxidative stress damage and the level of homocysteine in the brain of VaD rats. Western blot results showed that pro-apoptotic protein Bax and cleaved caspase 3 increased and anti-apoptotic protein Bcl-2 decreased in the hippocampi of VaD rats. But after LIG treatment, these changes were reversed. Moreover, Nissl staining result showed that LIG could reduce neuronal degeneration in VaD rats. Furthermore, LIG enhanced the expressions of P-AMPK and Sirtuin1(SIRT1) in VaD rats. In conclusion, these studies indicated that LIG could ameliorate cognitive impairment in VaD rats, which might be related to AMPK/SIRT1 pathway activation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code Availability

Not applicable.

References

Download references

Funding

This work was supported by the National Natural Science Foundation of China (82004430 and 81673717); the Natural Science Foundation of Guangdong (2021A1515011478 and 2018A0303130053) and Guangdong Provincial Key Laboratory of Research on Emergency in TCM (2017B030314176).

Author information

Authors and Affiliations

Authors

Contributions

Shi-Jie Zhang designed the experiments. Dong Peng carried out the experiments and wrote the manuscript. Dan Luo supported the animal work. Han-Zi Qiao, Hong-Yu Tan, Yi-Xue Wang, Li-Jun Qiao supported the materials. Dong Peng, Ye-Feng Cai and Shi-Jie Zhang modified the manuscript. Qi Wang supported the experimental platform. Li Guan and Shi-Jie Zhang supervised this work

Corresponding authors

Correspondence to Shi-Jie Zhang, Qi Wang or Li Guan.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Ethics approval

This study was approved by the Committee for Animal Research of Guangzhou University of Chinese Medicine.

Consent to Participate and Publication

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peng, D., Qiao, HZ., Tan, HY. et al. Ligustilide ameliorates cognitive impairment via AMPK/SIRT1 pathway in vascular dementia rat. Metab Brain Dis 37, 1401–1414 (2022). https://doi.org/10.1007/s11011-022-00947-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11011-022-00947-0

Keywords

Navigation